Literature DB >> 10501876

Surgery for chronic thromboembolic pulmonary hypertension.

R S Hartz1.   

Abstract

The modern era of surgery for chronic thromboembolic pulmonary hypertension (CTEPH) began just over 10 years ago. Until that time pulmonary thromboendarterectomy (PTE) was performed infrequently and essentially at a single medical center (University of California at San Diego-UCSD). It posed a formidable technical challenge and was associated with both high operative mortality (> 20%) and excessive morbidity due to respiratory and multiorgan system failure. Currently PTE is performed at numerous medical centers throughout the world, largely due to the pioneering efforts of those surgeons who developed and perfected the operation at UCSD. Operative mortality rates have fallen, and postoperative complications have become less common. Although no longer simply an autopsy curiosity, CTEPH continues to be an underdiagnosed condition. Increased awareness and better diagnosis will lead to curative surgery in more patients worldwide.

Entities:  

Mesh:

Year:  1999        PMID: 10501876     DOI: 10.1007/s002689900637

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  3 in total

1.  Short-term intravenous iloprost for treatment of reperfusion lung oedema after pulmonary thromboendarterectomy.

Authors:  Hsao-Hsun Hsu; Jin-Shing Chen; Yih-Sharng Chen; Wen-Je Ko; Shuenn-Wen Kuo; Yung-Chie Lee
Journal:  Thorax       Date:  2007-05       Impact factor: 9.139

2.  Perfusion techniques for pulmonary thromboendarterectomy under deep hypothermia circulatory arrest: a case series.

Authors:  Bingyang Ji; Jinping Liu; Yongbo Wu; Guyan Wang; Zhengyi Feng; Mingzheng Liu; Cun Long; Yunhu Song
Journal:  J Extra Corpor Technol       Date:  2006-12

3.  Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status.

Authors:  M C Zoia; A M D'Armini; M Beccaria; A Corsico; P Fulgoni; C Klersy; F Piovella; M Viganò; I Cerveri
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.